Kiadis appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team

  • Senior exec­u­tives with exten­sive biotech­nol­o­gy and phar­ma­ceu­ti­cal indus­try, sci­ence, inno­va­tion and busi­ness devel­op­ment expe­ri­ence 
  • Bringing unique capa­bil­i­ties to unlock broad poten­tial of Kiadis plat­form 

Amsterdam, The Netherlands, July 13, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive NK-cell ther­a­peu­tics for patients with life-threat­en­ing dis­eases, today announces that it has appoint­ed Ray Barlow, Ph.D. as chief busi­ness offi­cer and Govert Schouten, Ph.D. as head of inno­va­tion. As of today, Barlow and Schouten will report to Kiadis’ CEO, Arthur Lahr, and will be mem­bers of the Company’s Management Team. Marcel Zwaal, the Company’s senior vice pres­i­dent of cor­po­rate devel­op­ment, will be leav­ing the Company to pur­sue oth­er oppor­tu­ni­ties.

Dr. Barlow is respon­si­ble for all cor­po­rate busi­ness devel­op­ment ini­tia­tives, includ­ing out-licens­ing, phar­ma and biotech part­ner­ships, devel­op­ment and com­mer­cial­iza­tion col­lab­o­ra­tions, and poten­tial merg­ers and acqui­si­tions. Dr. Schouten is respon­si­ble for Kiadis’ intel­lec­tu­al prop­er­ty, sci­en­tif­ic and aca­d­e­m­ic col­lab­o­ra­tions, gov­ern­ment grants and in-licens­ing of sci­ence and IP to build Kiadis’ K-NK tech­nol­o­gy plat­form.

Arthur Lahr, chief exec­u­tive offi­cer of Kiadis, com­ment­ed, “Kiadis’ K-NK-cell ther­a­py plat­form has almost unlim­it­ed poten­tial for the treat­ment of can­cers, infec­tious dis­eases and oth­er life-threat­en­ing dis­eases. Ray and Govert have through­out their careers led hun­dreds of deals with phar­ma, biotech and acad­e­mia, and brought in hun­dreds of mil­lions in licens­ing fees and gov­ern­ment grants. They can make a huge con­tri­bu­tion to unlock the val­ue of our plat­form, for prod­ucts that we bring to mar­ket on our own or with the help of a big­ger phar­ma­ceu­ti­cal com­pa­ny. I want to thank Marcel for all of his con­tri­bu­tions to acquire and posi­tion our K-NK tech­nol­o­gy and wish him all the best in his future endeav­ors. We wel­come Ray and Govert and look for­ward to their con­tri­bu­tions to build our pipeline and our K-NK-cell ther­a­py plat­form.”

With more than 20 years of expe­ri­ence in the bio­phar­ma­ceu­ti­cal indus­try, Ray Barlow has served in var­i­ous lead­er­ship roles includ­ing most recent­ly as chief exec­u­tive offi­cer at e-ther­a­peu­tics PLC where he led the turn­around of the busi­ness and gen­er­at­ed its first com­mer­cial deals. Previously, Dr. Barlow worked at Amgen as exec­u­tive direc­tor of cor­po­rate devel­op­ment and pri­or to that at Crucell Vaccines where he man­aged busi­ness deals in infec­tious dis­eases and vac­cines. Prior to join­ing Crucell, Ray found­ed and led his own busi­ness, BD Solutions Ltd, advis­ing clients on cor­po­rate devel­op­ment and com­mer­cial­iza­tion strate­gies. Dr. Barlow start­ed his career at AstraZeneca where he held a num­ber of senior R&D, Business Development and Commercial roles over a 12-year peri­od. Dr. Barlow holds a Ph.D. in macro­mol­e­c­u­lar sci­ence from the University of Manchester, UK, a BSc in Chemistry from the University of Leeds, UK, and an MBA from Manchester Business School, UK.

Govert Schouten brings near­ly 25 years of expe­ri­ence in the phar­ma­ceu­ti­cal and biotech­nol­o­gy indus­try to Kiadis. Most recent­ly, Dr. Schouten was the founder of Idmon Consulting B.V., a con­sult­ing firm pro­vid­ing cor­po­rate devel­op­ment, strat­e­gy and busi­ness devel­op­ment ser­vices. Prior to that, Dr. Schouten was co-founder and chief busi­ness offi­cer of myTomorrows (Impatients N.V.), chief exec­u­tive offi­cer of Mucosis B.V., and vice pres­i­dent, head of busi­ness devel­op­ment and mem­ber of the exec­u­tive com­mit­tee of Crucell Vaccines. Dr. Schouten holds a Master’s degree in behav­ioral sci­ences and a Ph.D. in tumor virol­o­gy from Leiden University, The Netherlands.

Leave a Reply

Your email address will not be published. Required fields are marked *